Table 1. Baseline characteristics of study participants.
| HAND (n = 10) | nonHAND (n = 13) | Control (n = 11) | p-value | |
|---|---|---|---|---|
| Sex(male) | 100% | 100% | 100% | |
| Age(years) | 56.0±8.2 | 52.8±6.2 | 54.7±4.2 | 0.47 |
| BMI(kg/m2) | 23.6±2.0 | 22.3±2.4 | 25.2±2.0 | 0.018 |
| education (years) | 13.1±4.4 | 12.7±3.3 | 12.7±1.6 | 0.949 |
| Hemoglobin | 14.2±1.5 | 14.0±1.4 | 14.3±2.2 | 0.931 |
| eGFR | 80.7±15.3 | 82.5±10.6 | 85.6±7.5 | 0.585 |
| CD4 at diagnose (cells/uL, mean±SD) | 203.8±220.7 | 284.1±239.1 | 0.441 | |
| VL at diagnose (log10 copies/mL) (mean ± SD) | 5.5±5.5 | 4.3±4.3 | 0.019 | |
| pre ART CD4 (cells/uL, mean±SD) | 201.8±151.9 | 224.5±91.5 | 0.722 | |
| Pre ART VL (log10 copies/mL) (mean ± SD) | 5.2±5.5 | 4.8±4.9 | 0.304 | |
| current CD4 (cells/uL, mean±SD) | 525.8±252.2 | 697.9±194.2 | 0.078 | |
| current VL (log10 copies/mL) (mean ± SD) | 1.4±1.0 | 1.3±0.0 | 0.264 | |
| Nadir CD4 (cells/uL, mean±SD) | 188.9±183.1 | 216.8±147.9 | 0.69 | |
| Highest VL (log10 copies/mL) (mean ± SD) | 5.4±5.4 | 4.8±4.9 | 0.034 | |
| ART regimen (n, %) | ||||
| no treatment | 0 | 0 | ||
| 2NRTIs+PI | 6(60) | 5(38) | 0.327 | |
| 2NRTIs+NNRTI | 3(30) | 4(31) | 0.97 | |
| 2NRTIs+II | 1(10) | 4(31) | 0.251 | |
| CPE score(mean±SD) | 7.60±1.35 | 7.92±0.76 | 0.474 | |
| Change in ART | 5(50) | 5(38) | 0.6 |
Initial: at diagnose.